Methods for Treating HCV
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
1 . A method of treatment for HCV genotype 1, comprising administering at least two direct acting antiviral agents (DAAs) to a patient infected with HCV genotype 1, wherein said treatment lasts for 4 or 6 weeks and does not include administration of either interferon or ribavirin to said patient, wherein said at least two DAAs comprise Compound 1
Compound 2
Compound 4
and another DAA, and wherein Compound 1 is administered with ritonavir.
2 . The method of claim 1 , wherein said treatment lasts for 4 weeks.
3 . The method of claim 1 , wherein said treatment lasts for 6 weeks.
4 . The method of claim 1 , wherein said patient is a treatment-naïve patient.
5 . The method of claim 2 , wherein said patient is a treatment-naïve patient.
6 . The method of claim 3 , wherein said patient is a treatment-naïve patient.
7 . A method of modeling the relationship between DAA exposures and antiviral efficacy in HCV-infected subjects, wherein said modelling comprises modeling hepatocytes dynamics, infected cell dynamics, and viral dynamics.
8 . The method according to claim 7 , wherein said modeling comprises resolution or simulation of equation 1:
d VLPoly/ dt =(1−μφ)*ρ*(1−Eff2)*Fit1*IPoly+μ*ρ*(1−Eff1)*IWT+φ*ρ*(1−Eff5)*Fit4*IPoly−Prot− c *VLPoly Equation 1.